IRONWOOD PHARMACEUTICALS, INC. (IRWD) Spending and interest coverage
- R&D / revenue · 12 months: Value 22.78%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 3.68%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 22.78% | Research and development expense / revenue. Period ending 2026-06-30. $88.69M ÷ $389.32M × 100 ≈ 22.78% |
| Stock-based compensation / revenue · 12 months | 3.68% | Share-based compensation / revenue. Period ending 2026-06-30. $14.32M ÷ $389.32M × 100 ≈ 3.68% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 88.69M USD | Research and Development Expense |
| Revenue | 389.32M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 14.32M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 234.17M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $88.69M | $389.32M | $14.32M | $234.17M | (m) | 22.78% | 3.68% | (m) | (m) |
| 2026-03-31 | $89.64M | $361.51M | $15.61M | $200.18M | (m) | 24.80% | 4.32% | (m) | (m) |
| 2025-12-31 | $95.14M | $296.15M | $17.25M | $98.50M | (m) | 32.12% | 5.82% | (m) | (m) |
| 2025-09-30 | $98.66M | $338.99M | $17.99M | $123.19M | (m) | 29.11% | 5.31% | (m) | (m) |
| 2025-06-30 | $106.02M | $308.52M | $22.71M | $73.34M | (m) | 34.37% | 7.36% | (m) | (m) |
| 2025-03-31 | $113.04M | $317.68M | $26.76M | $53.00M | (m) | 35.58% | 8.42% | (m) | (m) |
| 2024-12-31 | $111.42M | $351.41M | $29.85M | $93.12M | (m) | 31.71% | 8.49% | (m) | (m) |
| 2024-09-30 | $121.71M | $378.42M | $33.99M | $99.22M | (m) | 32.16% | 8.98% | (m) | (m) |
| 2024-06-30 | $124.86M | $400.56M | $33.56M | $113.61M | (m) | 31.17% | 8.38% | (m) | (m) |
| 2024-03-31 | $129.05M | $413.55M | $33.26M | $-994.51M | $27.33M | 31.21% | 8.04% | -36.38× | Reported |
| 2023-12-31 | $116.08M | $442.74M | $32.01M | $-945.43M | $21.63M | 26.22% | 7.23% | -43.71× | Reported |
| 2023-09-30 | $90.86M | $432.38M | $30.59M | $-914.66M | $14.73M | 21.01% | 7.08% | -62.09× | Reported |
| 2023-06-30 | $69.42M | $427.28M | $29.75M | $-886.21M | $6.42M | 16.25% | 6.96% | -138.10× | Reported |
| 2023-03-31 | $46.29M | $417.13M | $28.09M | $252.59M | $6.78M | 11.10% | 6.73% | 37.23× | Reported |
| 2022-12-31 | $44.27M | $410.60M | $27.05M | $250.34M | $7.60M | 10.78% | 6.59% | 32.95× | Reported |
| 2022-09-30 | $65.67M | $420.53M | $25.85M | $238.57M | $14.02M | 15.62% | 6.15% | 17.01× | Reported |
| 2022-06-30 | $65.03M | $415.64M | $24.99M | $235.26M | $20.34M | 15.65% | 6.01% | 11.57× | Reported |
| 2022-03-31 | $65.74M | $422.44M | $22.97M | $244.71M | $25.86M | 15.56% | 5.44% | 9.46× | Reported |
| 2021-12-31 | $70.41M | $413.75M | $22.28M | $232.26M | $31.15M | 17.02% | 5.39% | 7.46× | Reported |
| 2021-09-30 | $54.82M | $413.30M | $26.20M | $227.05M | $30.72M | 13.26% | 6.34% | 7.39× | Reported |
| 2021-06-30 | $65.61M | $413.02M | $27.70M | $207.50M | $30.30M | 15.88% | 6.71% | 6.85× | Reported |
| 2021-03-31 | $75.52M | $398.43M | $30.21M | $175.11M | $29.88M | 18.95% | 7.58% | 5.86× | Reported |
| 2020-12-31 | $88.06M | $389.52M | $31.18M | $142.94M | $29.48M | 22.61% | 8.00% | 4.85× | Reported |
| 2020-09-30 | $98.33M | $399.14M | $26.65M | $141.15M | $29.08M | 24.64% | 6.68% | 4.85× | Reported |
| 2020-06-30 | $104.19M | $426.84M | $24.46M | $161.42M | $32.12M | 24.41% | 5.73% | 5.03× | Reported |
| 2020-03-31 | $110.87M | $439.63M | $23.71M | $150.28M | $34.23M | 25.22% | 5.39% | 4.39× | Reported |
| 2019-12-31 | $115.04M | $428.41M | $31.28M | $120.12M | $36.60M | 26.85% | 7.30% | 3.28× | Reported |
| 2019-09-30 | $182.19M | $432.80M | $39.60M | $12.17M | $39.06M | 42.10% | 9.15% | 0.31× | Reported |
| 2019-06-30 | $183.80M | $367.32M | $46.19M | $-200.29M | $38.09M | 50.04% | 12.58% | -5.26× | Reported |
| 2019-03-31 | $183.99M | $346.21M | $49.92M | $-257.40M | $38.04M | 53.14% | 14.42% | -6.77× | Reported |
| 2018-12-31 | $166.50M | $346.64M | $43.98M | $-238.89M | $37.72M | 48.03% | 12.69% | -6.33× | Reported |
| 2018-09-30 | $162.35M | $310.15M | $41.47M | $-222.12M | $37.34M | 52.34% | 13.37% | -5.95× | Reported |
| 2018-06-30 | $152.62M | $331.29M | $37.20M | $-72.46M | $37.00M | 46.07% | 11.23% | -1.96× | Reported |
| 2018-03-31 | $151.03M | $315.26M | $35.58M | $-73.55M | $36.66M | 47.91% | 11.29% | -2.01× | Reported |
| 2017-12-31 | $148.23M | $298.28M | $33.82M | $-77.39M | $36.37M | 49.69% | 11.34% | -2.13× | Reported |
| 2017-09-30 | $146.55M | $291.53M | $32.50M | $-106.45M | $36.82M | 50.27% | 11.15% | -2.89× | Reported |
| 2017-06-30 | $147.01M | $270.81M | $30.73M | $-115.30M | $37.45M | 54.29% | 11.35% | -3.08× | Reported |
| 2017-03-31 | $141.35M | $260.08M | $29.69M | $-89.61M | $38.23M | 54.35% | 11.42% | -2.34× | Reported |
| 2016-12-31 | $139.49M | $273.96M | $29.22M | $-51.87M | $39.15M | 50.92% | 10.67% | -1.32× | Reported |
| 2016-09-30 | $128.68M | $239.81M | $28.34M | $-51.40M | $39.48M | 53.66% | 11.82% | -1.30× | Reported |
| 2016-06-30 | $116.98M | $213.27M | $28.04M | $-49.30M | $39.74M | 54.85% | 13.15% | -1.24× | Reported |
| 2016-03-31 | $113.95M | $186.66M | $26.85M | $-75.99M | $35.78M | 61.04% | 14.38% | -2.12× | Reported |
| 2015-12-31 | $108.75M | $149.56M | $25.47M | $-102.09M | $31.10M | 72.71% | 17.03% | -3.28× | Reported |
| 2015-09-30 | $108.60M | $134.32M | $27.53M | $-129.39M | $26.38M | 80.85% | 20.50% | -4.91× | Reported |
| 2015-06-30 | $107.89M | $111.67M | $26.43M | $-139.94M | $21.67M | 96.62% | 23.67% | -6.46× | Reported |
| 2015-03-31 | $101.39M | $90.76M | $25.54M | $-153.05M | $21.10M | 111.71% | 28.13% | -7.25× | Reported |
| 2014-12-31 | $101.89M | $76.44M | $26.18M | $-169.37M | $21.17M | 133.30% | 34.26% | -8.00× | Reported |
| 2014-09-30 | $96.92M | $43.39M | $22.16M | $-182.98M | $21.20M | 223.36% | 51.07% | -8.63× | Reported |
| 2014-06-30 | $94.82M | $31.41M | $21.82M | $-202.79M | $21.15M | 301.89% | 69.48% | -9.59× | Reported |
| 2014-03-31 | $96.77M | $34.23M | $20.63M | $-207.56M | $21.16M | 282.69% | 60.26% | -9.81× | Reported |
| 2013-12-31 | $102.38M | $22.88M | $19.83M | $-252.00M | $21.00M | 447.44% | 86.66% | -12.00× | Reported |
| 2013-09-30 | $108.14M | $44.83M | $19.95M | $-249.16M | $15.72M | 241.21% | 44.51% | -15.85× | Reported |
| 2013-06-30 | $108.57M | $136.31M | $19.89M | $-145.00M | $10.47M | 79.65% | 14.59% | -13.85× | Reported |
| 2013-03-31 | $116.72M | $141.25M | $19.13M | $-125.96M | $5.17M | 82.63% | 13.54% | -24.38× | Reported |
| 2012-12-31 | $113.47M | $150.25M | $17.57M | $-72.76M | $59.00K | 75.53% | 11.70% | -1233.25× | Reported |
| 2012-09-30 | $109.42M | $155.42M | $16.13M | $-35.89M | $55.00K | 70.41% | 10.38% | -652.62× | Reported |
| 2012-06-30 | $108.88M | $71.22M | $13.86M | $-105.12M | $57.00K | 152.87% | 19.46% | -1844.18× | Reported |
| 2012-03-31 | $96.05M | $67.88M | $12.76M | $-83.24M | $61.00K | 141.49% | 18.79% | -1364.52× | Reported |
| 2011-12-31 | $86.09M | $65.87M | $11.73M | $-66.14M | $63.00K | 130.70% | 17.81% | -1049.87× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | $45.26M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $77.45M | $43.86M | $7.50M | $-60.77M | $196.00K | 176.61% | 17.09% | -310.03× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $76.10M | $34.32M | $5.09M | $-60.82M | $318.00K | 221.73% | 14.85% | -191.25× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |